

16 October 2024

Enlitic Signs Three-Year Distribution Agreement with Bayer Healthcare for Enlitic's ENDEX

Highlights

- Enlitic signs three-year platform distribution agreement with multinational biomedical company, Bayer Healthcare
- Once validation testing has been successfully completed, ENDEX will be integrated into and distributed alongside Bayer's radiation dose management proprietary software products to support radiation dose monitoring
- Initial rollout to up to 50 radiology sites, with the potential for expansion to up to 200 sites.
- This is the third collaboration between Enlitic and Bayer, and will expand ENDEX into a new use case: Radiation Dosimetry for radiation dose monitoring
- Assuming successful completion of validation testing, Enlitic expects this new use case for ENDEX under the agreement to contribute to revenue approximately US\$50k per annum during the term of the agreement (which may potentially increase if the opportunity for expansion of sites is realised).

Enlitic, Inc. (ASX: ENL) ("the Company") is pleased to announce it has signed a three-year distribution contract with Bayer Healthcare, LLC for its ENDEX product for Radiation Dosimetry.

Once validation testing has been successfully completed, ENDEX will be integrated into Bayer's radiation dose management proprietary software products, to support patient radiation dose monitoring. ENDEX will initially be rolled out to an agreed number of radiologist sites .

Bayer Healthcare is one of the largest pharmaceutical and biomedical companies in the world, offering products and services that empower radiologists to deliver high-quality contrast-enhanced imaging in CT and MR.

Bayer's radiation dose management proprietary software products intelligently connects information on radiation dose, contrast agents, injector and scan information into a software solution that provides critical insights to radiology teams. This helps deliver more personalised care to patients and achieve reproducible quality, in line with radiation standards and regulations.

The integration of Enlitic's ENDEX solution will enhance Bayer's software by standardising the imaging data and support enhanced decision-making by clinicians. The agreement enables the ENDEX

product to be used at up to 50 radiology customer sites, with scope to expand to up to 200 sites globally.

Michael Sistenich, CEO of Enlitic, said “We are incredibly excited to be working with the team at Bayer to support them with radiation dose monitoring to their customers. Ensuring patient radiation doses remain within safe limits is critical to providing high-quality care. ENDEX supports monitoring by ensuring universal terminology is applied, helping to inform better decision-making by clinicians and staff. This Partnership opens a new and exciting use case for ENDEX in radiation dosimetry and highlights our potential to expand the value of Enlitic’s solutions.”

– ENDS –

This announcement was authorised for release by the Board of Enlitic, Inc.

Enquiries

Enlitic Investor Relations

Australia:
invest_au@enlitic.com

USA:
invest@enlitic.com

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people, and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, Bayer aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability, and quality throughout the world. In fiscal 2022, the Group employed around 99,723 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to www.bayer.com.

About Enlitic

Enlitic is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT scans, X-ray and ultrasound images) and licences such products to healthcare providers. Enlitic’s products (including its current product offering and product suite under development) seek to standardise, protect, integrate, and analyse data to create the foundation of a real-world evidence platform that can improve clinical workflows, increase efficiencies, and expand capacity. Read more at enlitic.com.